Product Details

Verdefla Oral Suspension meets pharmacopoeial standards for the management of inflammatory and autoimmune conditions. Specifically, each 5ml delivers Deflazacort IP at 6mg, in a flavoured base. As a result, it offers effective corticosteroid therapy in a convenient, accurately dosed liquid formulation suited to children and patients who have difficulty swallowing tablets.

The suspension contains:

• Deflazacort IP (6mg per 5ml, in a flavoured base) – A synthetic corticosteroid with potent anti-inflammatory and immunosuppressive activity. Consequently, it suppresses inflammation and modulates immune response, offering a comparatively favourable bone and metabolic safety profile relative to some other corticosteroids.

Physicians prescribe Verdefla for the management of a range of inflammatory and autoimmune conditions, including certain forms of muscular dystrophy, severe asthma, autoimmune disorders, and other conditions requiring corticosteroid therapy. In addition, the calibrated dosing cap supports accurate, weight-based dosing, particularly important for children on long-term corticosteroid treatment. Because of this profile, Verdefla suits paediatric, neurology, and rheumatology settings managing chronic inflammatory conditions.

Key Features:

• Overall, this formulation guarantees pharmaceutical-grade purity
• Additionally, the calibrated dosing cap supports precise, accurate administration
• Furthermore, each 5ml delivers precise, validated dosage accuracy at 6mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, amber bottle packaging protects the light-sensitive formulation
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies